STAAR Surgical (NASDAQ:STAA) Holdings Raised by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its stake in shares of STAAR Surgical (NASDAQ:STAA) by 411.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 214,750 shares of the medical instruments supplier’s stock after buying an additional 172,779 shares during the period. JPMorgan Chase & Co. owned about 0.44% of STAAR Surgical worth $7,978,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of STAA. Geode Capital Management LLC lifted its holdings in shares of STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock valued at $43,641,000 after purchasing an additional 31,212 shares in the last quarter. Mutual of America Capital Management LLC grew its holdings in shares of STAAR Surgical by 214.7% during the second quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier’s stock valued at $1,260,000 after buying an additional 18,051 shares in the last quarter. HighTower Advisors LLC acquired a new position in STAAR Surgical during the third quarter valued at $336,000. Algert Global LLC lifted its stake in STAAR Surgical by 13.5% in the 2nd quarter. Algert Global LLC now owns 116,655 shares of the medical instruments supplier’s stock worth $5,554,000 after acquiring an additional 13,901 shares in the last quarter. Finally, Granite Investment Partners LLC acquired a new position in shares of STAAR Surgical in the second quarter worth $17,237,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 7th. Canaccord Genuity Group dropped their price objective on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th. Finally, Stephens raised shares of STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $42.83.

STAAR Surgical Stock Performance

STAA opened at $21.65 on Wednesday. The firm has a market cap of $1.07 billion, a P/E ratio of 49.20 and a beta of 0.63. The business has a 50 day moving average price of $26.07 and a 200 day moving average price of $32.42. STAAR Surgical has a twelve month low of $21.13 and a twelve month high of $52.68.

Insider Buying and Selling

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 53,500 shares of the company’s stock in a transaction on Monday, December 16th. The shares were bought at an average cost of $24.24 per share, with a total value of $1,296,840.00. Following the transaction, the insider now directly owns 10,821,931 shares in the company, valued at approximately $262,323,607.44. This represents a 0.50 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.00% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.